SAGE - Sage Therapeutics, Inc.
| Previous Close | 171.03 |
| Open | 169.75 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 169.30 - 177.10 |
| 52 Week Range | 79.88 - 177.10 |
| Volume | 466,870 |
| Avg. Volume | 511,700 |
| Market Cap | 8.999B |
| Beta (3Y Monthly) | 3.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.79 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 201.00 |
- Simply Wall St.•20 hours ago
Are Investors Undervaluing Sage Therapeutics, Inc. (NASDAQ:SAGE) By 29%?
How far off is Sage Therapeutics, Inc. (NASDAQ:SAGE) from its intrinsic value? Using the most recent financial data...
- Zacks•3 days ago
Ligand Grants Preclinical Candidate Rights to UK-based Firm
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
- Business Wire•9 days ago
Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference
Sage Therapeutics , a biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the 2019 RBC Capital Markets Global Healthcare Conference on Tuesday, May 21, 2019 at 3:35 p.m.
- Thomson Reuters StreetEvents•9 days ago
Edited Transcript of SAGE earnings conference call or presentation 2-May-19 12:00pm GMT
Q1 2019 SAGE Therapeutics Inc Earnings Call
- American City Business Journals•14 days ago
New England Venture Capital Association names 2019 NEVY Awards winners
The final winners are selected by the NEVYs Technology, Healthcare and Life Sciences Academies among a pool of nominees revealed in March. This year's seventh annual NEVYs marked the first time the Healthcare category had a dedicated Academy distinct from Life Sciences.
- Motley Fool•15 days ago
Small-Cap Stocks to Watch in May
These two companies are set to announce important business updates this month.
- Business Wire•15 days ago
Sage Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference
Sage Therapeutics , a biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019 at 8:40 a.m.
- Markit•16 days ago
See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.
SAGE Therapeutics Inc NASDAQ NMS:SAGEView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is moderately high for SAGE with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.47 billion over the last one-month into ETFs that hold SAGE are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•16 days ago
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 21,680 shares of its common stock, and 6,280 performance restricted stock units (PSUs) to six new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- Business Wire•21 days ago
Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics, Inc. (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter ended March 31, 2019. “We started 2019 with positive data from a Phase 3 clinical trial of our lead oral compound SAGE-217 in postpartum depression and this was quickly followed by the FDA approval of ZULRESSO in PPD,” said Jeff Jonas, M.D., chief executive officer at Sage.
- ACCESSWIRE•21 days ago
SAGE Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 2, 2019 / SAGE Therapeutics, Inc. (NASDAQ: SAGE ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 2, 2019 at 8:00 AM Eastern ...
- GlobeNewswire•24 days ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Sage Therapeutics, Inc.
NEW YORK, April 29, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Sage Therapeutics, Inc. (NASDAQGM: SAGE) concerning possible breaches of.
- CNBC•26 days ago
Sage Therapeutics' Zulresso is a big win for postpartum depression sufferers — and maybe even the entire mental health community
In June, Zulresso — the first and only medicine approved by the Food and Drug Administration to specifically treat postpartum depression — will hit the market. Sage Therapeutics, the maker of the drug, now hopes to win the fight against another major issue: The public's misconception about mental health.
- American City Business Journals•27 days ago
Analysts point to potential Biogen M&A options after Alzheimer's failure
Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.
- Insider Monkey•29 days ago
Did Hedge Funds Drop The Ball On SAGE Therapeutics Inc (SAGE) ?
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
- Business Wire•last month
Sage Therapeutics to Report First Quarter 2019 Financial Results on Thursday, May 2, 2019
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, May 2, 2019 at 8:00 A.M. ET to report its first quarter 2019 financial results and to discuss recent business updates. The live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.
- Zacks•2 months ago
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
Market Realist•2 months agoMost Analysts Have Been Positive on Sage Therapeutics in March
Analysts Are Feeling Good about These Biotech Stocks in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 26.25% for Sage Therapeutics (SAGE) based on the company’s
- MarketWatch•2 months ago
5 biotech stocks that could be the next big winners
Biotech stocks are some of the most exciting investments on Wall Street. When one company develops a successful treatment for a complex condition, shares can surge overnight and attract buyout interest from Big Pharma. Case in point: Biotech giant Biogen (BIIB) imploded roughly 30% on Thursday after announcing it is canceling its Alzheimer’s drug efforts after poor drug trials.
- Motley Fool•2 months ago
2 Biotech Takeout Targets Perfect for Biogen
A midsize acquisition seems imminent, and these two would fit like a glove.
- TheStreet.com•2 months ago
A Big Outside Day and Lower Close on Sage Therapeutics Looks Bearish to Me
, which just received FDA approval for Zulresso, the first treatment for postpartum depression. Dr. Jonas said that postpartum depression is the most common complication for women after childbirth, and suicide remains a leading cause of death among adults overall.
- CNBC Videos•26 days ago
How a failed epilepsy drug became a $34,000 postpartum cure
According to the Centers for Disease Control and Prevention, 1 in 9 women in the United States experience symptoms of postpartum depression. Looking at individual states, postpartum depression can affect as many as 1 in 5 women. In March 2019, the FDA approved the first postpartum depression drug, developed by Sage Therapeutics. Led by CEO Jeff Jonas, Sage Therapeutics created the treatment by taking a different approach toward mental health.
